TY - JOUR
T1 - Changes in passively-sensitized basophil activation to αS1-casein after oral immunotherapy
AU - Matsui, Teruaki
AU - Naito, Michihiro
AU - Tagami, Kazunori
AU - Tajima, Iwao
AU - Teshigawara, Miyuki
AU - Makino, Atsushi
AU - Kitamura, Katsumasa
AU - Takasato, Yoshihiro
AU - Sugiura, Shiro
AU - Yamada, Chikako
AU - Izumi, Hidehiko
AU - Tsuge, Ikuya
AU - Kondo, Yasuto
AU - Ito, Komei
N1 - Funding Information:
The authors are grateful to the former staff of Aichi Children's Health and Medical Center for their clinical contribution to performing OIT and collecting the serum samples for many years. The authors would also like to thank Enago for the English Language review. This study was partially funded by a grant of the Nipponham Foundation for the Future of Food.
Publisher Copyright:
© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Introduction: Immune response to cow's milk allergen (CMA) has been analyzed mostly using crude milk antigen or a mixture of various caseins. This study aimed to assess the changes in the immunological response against αS1-casein during oral immunotherapy (OIT) and to investigate the mechanism of tolerance. Methods: We have performed rush OIT to 39 patients with CMA and obtained the serum samples up to 3 years after OIT. Immunoglobulin E (IgE) and IgG4 antibodies specific to highly purified αS1-casein as well as passively-sensitized basophil activation were evaluated using the serial samples. Furthermore, we examined whether basophil activation led by the pre-OIT serum was suppressed by the post-OIT serum, or by the tolerant serum obtained from naturally outgrown patients. Results: Specific IgE to αS1-casein was significantly reduced after OIT. Specific IgG4 (sIgG4) to αS1-casein was also detected in most of the pre-OIT sera, which was not significantly increased after OIT. Activation of passively-sensitized basophils to αS1-casein was significantly reduced after 2 years (14% ± 19%) and 3 years (19% ± 18%) post-OIT compared with pre-OIT (%CD63high basophils; 51% ± 27%). Furthermore, the addition of post-OIT or tolerant serum to pre-OIT serum significantly suppressed the basophil activation. This suppression was abrogated by washing the supernatant after passive sensitization, but not by depleting IgG antibodies from post-OIT or tolerant sera, nor by blocking FcγRIIb using an anti-FcγR antibody. Conclusions: αS1-casein-sIgG4 plays a minor role in tolerance mechanisms in cases of CMA; humoral factors other than antigen-sIgG4 may be involved.
AB - Introduction: Immune response to cow's milk allergen (CMA) has been analyzed mostly using crude milk antigen or a mixture of various caseins. This study aimed to assess the changes in the immunological response against αS1-casein during oral immunotherapy (OIT) and to investigate the mechanism of tolerance. Methods: We have performed rush OIT to 39 patients with CMA and obtained the serum samples up to 3 years after OIT. Immunoglobulin E (IgE) and IgG4 antibodies specific to highly purified αS1-casein as well as passively-sensitized basophil activation were evaluated using the serial samples. Furthermore, we examined whether basophil activation led by the pre-OIT serum was suppressed by the post-OIT serum, or by the tolerant serum obtained from naturally outgrown patients. Results: Specific IgE to αS1-casein was significantly reduced after OIT. Specific IgG4 (sIgG4) to αS1-casein was also detected in most of the pre-OIT sera, which was not significantly increased after OIT. Activation of passively-sensitized basophils to αS1-casein was significantly reduced after 2 years (14% ± 19%) and 3 years (19% ± 18%) post-OIT compared with pre-OIT (%CD63high basophils; 51% ± 27%). Furthermore, the addition of post-OIT or tolerant serum to pre-OIT serum significantly suppressed the basophil activation. This suppression was abrogated by washing the supernatant after passive sensitization, but not by depleting IgG antibodies from post-OIT or tolerant sera, nor by blocking FcγRIIb using an anti-FcγR antibody. Conclusions: αS1-casein-sIgG4 plays a minor role in tolerance mechanisms in cases of CMA; humoral factors other than antigen-sIgG4 may be involved.
UR - http://www.scopus.com/inward/record.url?scp=85080979957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080979957&partnerID=8YFLogxK
U2 - 10.1002/iid3.294
DO - 10.1002/iid3.294
M3 - Article
C2 - 32125071
AN - SCOPUS:85080979957
VL - 8
SP - 188
EP - 197
JO - Immunity, inflammation and disease
JF - Immunity, inflammation and disease
SN - 2050-4527
IS - 2
ER -